Weighty Matters: Balancing Weight Gain with Cardiovascular Risk among Patients with Type 1 Diabetes on Intensive Insulin Therapy.

BWH & Harvard Med School, Boston, MA.
Circulation (Impact Factor: 14.95). 12/2012; DOI: 10.1161/CIRCULATIONAHA.112.152777
Source: PubMed

ABSTRACT Type 1 diabetes, characterized by a deficiency of insulin production due to damaged pancreatic beta cells, is associated with a 10-fold increase in the risk of cardiovascular disease as compared to the general population.(1,2) Intensive insulin therapy, whether administered by multiple daily injections or continuous infusion via a pump, is the cornerstone of glycemic control in the patient with type 1 diabetes.(3) Most of what we know regarding the benefits of intensive insulin therapy is derived from the Diabetes Control and Complications Trial (DCCT), a trial of patients with type 1 diabetes who were randomized to either intensive or conventional insulin treatment.